New benzimidazole–indole–amide derivatives as potent α‐glucosidase and acetylcholinesterase inhibitors
Archiv der Pharmazie · 2025
DOI: 10.1002/ardp.202400354 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archiv der Pharmazie, 2025. Verfasst von Narges Naimi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran…. Hauptthemen laut MEDLINE: Glycoside Hydrolase Inhibitors, Cholinesterase Inhibitors, Molecular Docking Simulation, Benzimidazoles. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: None.
Abstract (Originalsprache)
New derivatives 6a–m with benzimidazole–indole–amide scaffold were developed, synthesized, and assessed for potential inhibitory effects on α‐glucosidase and acetylcholinesterase (AChE). These compounds were synthesized by various amine derivatives. With the exception of two compounds, the α‐glucosidase inhibitory activities of the title derivatives were more than that of the positive control acarbose. Moreover, the anti‐AChE activity of these compounds, with the exception of one compound, was better than that of tacrine (standard inhibitor). The most potent compound against α‐glucosidase was 3‐methylphenyl derivative 6i and the most potent compound against AChE was 3,4‐dimethoxyphenethyl derivative 6m . All the synthesized compounds were placed in the active sites of α‐glucosidase and AChE by in silico docking method and the obtained binding energies were approximately in agreement with the in vitro observed data. Interaction modes of the most potent compounds 6i and 6m demonstrated that these compounds interacted with important residues of their target enzymes. Molecular dynamics simulation was conducted specifically on compound 6i in complex with α‐glucosidase to obtain deeper insights into the behavior of this molecule. Furthermore, in silico pharmacokinetic and toxicity studies on the most potent compound predicted that these compounds have good profiles in terms of oral absorption and toxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
- Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
- Cellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran.
- Drug Design and Development Research Center, The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran.
- Department of Chemistry, Faculty of Science, Eskişehir Technical University, Eskişehir, Turkey.
- Vocational School of Health Service, Inonu University, Malatya, Turkey.
Förderung
- None
Zitieren
APA
Naimi, N., Karimian, S., Dastyafteh, N., Noori, M., Mohammadi-Khanaposhtani, M., Dadgar, A., Larijani, B., Lotfi, V., Çelik, İ., Aktaş, A., Sadeghian, N., Taslimi, P., & Mahdavi, M. (2025). New benzimidazole–indole–amide derivatives as potent α‐glucosidase and acetylcholinesterase inhibitors. Archiv der Pharmazie. https://doi.org/10.1002/ardp.202400354
Vancouver
Naimi N, Karimian S, Dastyafteh N, Noori M, Mohammadi-Khanaposhtani M, Dadgar A, et al. New benzimidazole–indole–amide derivatives as potent α‐glucosidase and acetylcholinesterase inhibitors. Archiv der Pharmazie. 2025. doi:10.1002/ardp.202400354
BibTeX
@article{Naimi2025,
author = {Naimi, Narges and Karimian, Somaye and Dastyafteh, Navid and Noori, Mild and Mohammadi-Khanaposhtani, Maryam and Dadgar, Armin and Larijani, Bagher and Lotfi, Vahid and Çelik, İlhami and Aktaş, Aydın and Sadeghian, Nastaran and Taslimi, Parham and Mahdavi, Mohammad},
title = {New benzimidazole–indole–amide derivatives as potent α‐glucosidase and acetylcholinesterase inhibitors},
journal = {Archiv der Pharmazie},
year = {2025},
doi = {10.1002/ardp.202400354}
}
EUVIMED